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Department of Vascular Surgery, Dundee Teaching Hospitals NHS Trust, Ninewells Hospital and 
Medical School, Dundee, U.K. 
Objective: To assess the long-term patency of a modified biological conduit, the glutaraldehyde-tanned bovine carotid 
artery, in above-knee infrainguinal arterial reconstruction. 
Patients and Methods: Prospective follow-up of a cohort of 58 above-knee f moropopliteaI grafts in 55 patients. Graft 
patency was assessed at yearly intervals with doppler ankle pressure measurements. 
Results: The median follow-up period has been 67 months. Nine grafts occluded within 30 days of surgery and a further 
19 graft closures have been observed in the follow-up period. The overall cumulative primary graft patency at 1, 3 and 
5 years was 70%, 61% and 56%, respectively. If the 30-day graft failures are excluded, the primary graft patency rises 
to 83%, 74% and 68% at 1, 3 and 5 years, respectively. Six limbs have been amputated, four above the knee and two 
below the knee. There were no graft aneurysms and no graft infections. 
Conclusion: Results indicate that the modified bovine carotid artery graft with an above-knee anastomosis does not seem 
to be inferior to PTFE, but is inferior to reversed vein. Modified biological conduits offer a reasonable alternative to 
synthetic grafts for infrainguinaI arterial reconstruction and appear to maintain acceptable ong-term mechanical stability. 
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Introduction 
Experience with the use of biological vascular grafts 
reached apeak 10 years ago with the use of the human 
umbilical vein allograft for femoropopliteal bypasses. 1 
In comparative studies, umbilical vein grafts have 
proven superior to Polytetra-fluoroethylene (PTFE) in 
infrainguinal reconstruction. 2'3 The early umbilical vein 
grafts were associated with a high incidence of graft 
degeneration a d aneurysm formation of up to 46%, 4 
the method of glutaraldehyde fixation was modified, 
and the newer grafts have a lower risk of such com- 
plications, of the order of 17%. 5 Nevertheless, there 
has been a general opinion that all biological sub- 
stitutes may be prone to the same complications, and 
in Europe PTFE grafts have become the preferred 
conduit by most surgeons when the autologous 
saphenous vein is absent or of inadequate size. 6 
The BioPolyMeric (BPM) graft (St Jude Medical, Inc., 
Minnesota, U.S.A.) is a glutaraldehyde-tanned bovine 
carotid artery. Some early clinical results with the BPM 
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graft for infrainguinal rterial reconstruction were en- 
couraging, 7 and one study had primary patencies of 
90% and 80% at 1 and 2 years, respectively. 8 This 
suggested that the BPM graft achieved results imilar 
to those of autologous saphenous vein. However, ini- 
tial results with the use of another infrainguinal-fixed 
bovine carotid artery graft (Solcograft) were dis- 
astrous, with a high incidence of early graft de- 
terioration and aneurysm formation, and appeared to 
confirm that this type of graft was prone to de- 
generation. 9 
We report our long-term follow-up of patency of 
the BPM graft. 
Patients and Methods 
Between July 1988 and November 1991, 58 BPM grafts 
were implanted for infrainguinal vascular re- 
construction i our institution. The majority of these 
grafts were inserted prior to the authors joining the 
institution. At that time it was believed that synthetic 
grafts used for above-knee r construction gave as good 
results as vein, and during this period the BPM graft 
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Fig. 1. Cumulative primary graft patency rates for the BPM graft (n =58). For a general comparison, our own primary patency rates for 
above-knee vein (n = 53) and PTFE (n = 85) grafts inserted since 1991 are also illustrated. Survival curves for PTFE and vein are calculated 
to the point at which the numbers become so small that standard error exceeds 10%. The numbers of grafts at risk after each 200-day 
interval are also illustrated. 
was used as the pr imary conduit for all above-knee 
reconstructions. These grafts were inserted as part of 
a clinical trial, and accurate fol low-up records have 
been maintained and the grafts have been reviewed 
continuously ever since. 
Doppler ultrasound ankle pressures were routinely 
performed pre- and postoperatively, and were used 
as an objective method of assessment of graft patency. 
When doubt existed as to the patency of the graft, 
arteriography was used as confirmatory evidence. 
Patients were seen at 3, 6 and 12 months, and yearly 
thereafter. A total of 58 BPM grafts were inserted in 
55 patients. There were 26 women and 32 men. The 
median age of the patients was 68 (inter-quartile range 
60-73). Five patients were diabetic (9%) and 39 (71%) 
were active smokers prior to graft insertion. Details 
of how many continued to smoke after surgery are 
unavailable. The indications for surgery were disabling 
claudication in 53 l imbs (91%) and rest pain in five. 
Since 1991 we have used vein as the pr imary above- 
knee conduit. In the absence of vein, PTFE has been 
used as the alternative material for above-knee re- 
construction. Since 1991, accurate fol low-up data has 
also been collected for PTFE and vein grafts. Cumu-  
lative patency rates for PTFE and vein since 1991 are 
also presented for comparison purposes. However,  in 
view of the fact that these grafts were inserted by 
different surgeons, for different indications, and that 
this was not a controlled comparative study, these 
other graft materials are not discussed in detail. 
Cumulative graft patency are calculated by Kaplan-  
Meier life-table analysis and patencies compared by 
the log-rank test using a computerised survival ana- 
lysis package (GraphPad Prism, GraphPad Software, 
Inc., San Diego, California, U.S.A.). 
Results 
There were no operative deaths. The median follow- 
up of all grafts is 67 months (IQ range 39-76 months) 
and for those patients till alive the median follow-up 
is 73 months (IQ range 61-77 months). Forty-five limbs 
have been followed up for at least 3 years, and 34 for 
more than 5 years. Thirty-two grafts (55%) remain 
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patent, with a median follow-up of 69 months (IQ 
range 39-73 months). 
The cumulative primary graft patency rates for the 
BPM graft are summarised in Fig. 1. This has been 
compared with our own subsequent patency rates for 
PTFE and vein since 1991. The overall cumulative 
primary graft patency for the BPM graft was 70%, 
65%, 61%, 59% and 56% at 1-5 years, respectively. 
There was no statistical difference between the graft 
patency of the three materials. 
Nine grafts occluded within 30 days of surgery and 
a further 19 grafts have closed in the follow-up period. 
Five of the early graft closures occurred in the first 13 
grafts inserted, and four in the latter 45. This apparent 
"learning curve" in inserting rafts did reach statistical 
significance 0¢2=6.73, p<0.01). If the nine early graft 
failures are excluded on the basis that they were due 
to technical errors, the cumulative primary patency 
rates rise to 83%, 79%, 74%, 71% and 68% at 1-5 years, 
respectively. Nine patients have died with functioning 
grafts after 3, 4, 15, 21, 31, 39, 44, 53 and 71 months, 
and five further patients have died with closed grafts. 
One of the immediate graft failures resulted in a 
below-knee amputation 6 months later. Five other 
limbs have been amputated, one below the knee at 60 
months and four above the knee after 9, 13, 17 and 65 
months; all for late graft failures. 
There have been no graft infections and no graft 
aneurysms have been found clinically. 
Discussion 
The first modified bovine carotid artery graft was used 
in 1963.1° The carotid artery of the adult cow was 
dialdehyde-tanned to strengthen the graft by cross- 
linking the collagen molecules. A high incidence of 
aneurysms and graft infections were reported, and 
this graft was abandoned. 1° Many of the problems 
with these early bovine heterografts were thought o 
be due to the dialdehyde starching. This led to the 
development of the glutaraldehyde-tanned bovine ca- 
rotid artery graft. 
There are no long-term reports regarding BPM graft 
performance in infrainguinal arterial reconstruction. 
In 1992, Wagner published his early results in a series 
of 112 grafts implanted for severe peripheral vascular 
disease. Primary patencies at 1 and 2 years were 90% 
and 80% to the above-knee popliteal artery. No graft 
aneurysms or dilatation were observed and there were 
few infectious complications. 8 
Another series of bovine carotid artery grafts (the 
Solcograft) deserves mention. 9 In this series, eight of 
26 grafts underwent severe degeneration within 4 
months of insertion. This appeared to be in con- 
tradiction to the manufacturer's data, which showed 
only four aneurysms forming in a series of 700 grafts. 9
Nevertheless, this disastrous experience with this 
single graft led to its withdrawal from production. 
Our results suggest that the BPM graft achieves 
long-term patency inferior to autologous vein but 
superior to PTFE. Although the difference between 
the BPM graft and the other two was not statistically 
significant, this may be a function of the relatively 
small numbers and short follow-up of the PTFE and 
vein grafts. In addition, in view of the fact that this 
was not a controlled clinical trial, it is difficult to imply 
too much significance from this finding, due to a 
possible different case mix and different surgeons. 
There is, however, a distinct trend for the patency of 
vein and BPM grafts to plateau after 1 year, whereas 
there appears to be constant attrition rate of PTFE 
grafts. 
It is difficult for us to explain the nine early graft 
failures because these grafts were not inserted by 
ourselves. However, there does appear to be a learning 
curve in using the graft, and it is important hat it is 
cut to exactly the right length. It must be assumed 
that these nine failures within 30 days can be attributed 
to technical errors which may have been overcome if
the grafts had been revised. Seven of the other 19 graft 
failures occurred between 100 and 365 days, and it is 
reasonable to assume that these were due to intimal 
hyperplasia. The remainder of the graft failures are 
spread out and probably represent disease pro- 
gression. 
This series also questions the generally held opinion 
that all biological prosthesis are prone to developing 
aneurysmal dilatation. Previous experience with 
human umbilical vein had shown that graft aneurysms 
usually develop between 40 and 80 months after sur- 
gery. 12 The issue of graft biodegradation has remained 
a major concern, preventing widespread use of bio- 
logical conduits in peripheral vascular surgery. The 
BPM graft appears to retain most of its mechanical 
properties even after 5 years, with no graft aneurysms 
clinically, although detailed duplex follow-up would 
be required to substantiate this claim. Experimental 
studies in a canine model have demonstrated that, 45 
months after implantation, most of the original bovine 
heterograft has been replaced by host tissues. 13 It is 
possible to speculate that the biological prosthesis acts 
as a bioresorbable scaffold and mechanical integrity 
of the graft is promoted by the orderly replacement 
of structural elements. 13
It is unfortunate that this graft is no longer 
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manufactured, as further long-term experience, 
particularly to the infrageniculate v ssels, would have 
been very informative. The modified bovine carotid 
artery graft appeared to offer a reasonable alternative 
to synthetic grafts for infrainguinal arterial re- 
construction when vein was absent or of inadequate 
size. In view of our experience, we feel that concern 
regarding biodegradation and aneurysmal dilatation 
should not have prevented the further development 
of vascular prosthesis of biological origin. 
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